Leerink raises 89bio stock target to $37 on NASH study optimism
Leerink Partners analyst Thomas Smith adjusted the price target for 89bio Inc . (NASDAQ:ETNB) to $37 from $34, while ...
pharmaphorum2 天
Novo Nordisk grabs NASH drug from Ventus in $703m deal
Along with NASH, Novo Nordisk is also planning to investigate ... phase 3 in combination with drugs from Gilead, a long-acting FGF21 analogue in phase 2, and early-stage candidates partnered ...
pharmaphorum3 天
Another NASH setback as Akero’s efruxifermin stumbles
due to NASH, a form of non-alcoholic fatty liver disease (NAFLD). In the 182-patient study, patients were treated with one of two doses of the FGF21 mimic or placebo - given as a once-weekly ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Fintel on MSN1 天
Wolfe Research Initiates Coverage of 89bio (ETNB) with Outperform Recommendation
Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of 89bio (NasdaqGM:ETNB) with a Outperform ...
Rolling Stone5 天
Stephen Stills and Graham Nash Reunite for First Time in Nearly a Decade at FireAid
Stephen Stills and Graham Nash performed together for the first time in nearly a decade at the Kia Forum’s FireAid benefit. They broke out the 1970 CSNY classic “Teach Your Children,” backed ...
Leerink上调89bio股票目标价至37美元，看好NASH研究前景
周一，Leerink Partners分析师Thomas Smith将89bio Inc. (NASDAQ: ETNB )的目标价从34美元上调至37美元，同时重申对该股的"优于大市"评级。目前，该股交易价格为9.60美元，远低于分析师12美元至49美元的更广泛目标区间。根据 InvestingPro ...
Frontiers3 天
Toxicokinetics of recombinant human fibroblast growth factor 21 for injection in cynomolgus ...
Introduction: Recombinant human fibroblast growth factor 21 (FGF-21) is a potential therapeutic agent for multiple metabolic diseases. However, little is known about the toxicokinetic characteristics ...
MarketWatch1 天
Akero Therapeutics Inc.
Roche Holding AG Akt-0.78% CHF230.86B ...
美股内部交易 | Akero Therapeutics于2月5日披露2笔公司内部人交易情况
2025年2月5日， Akero Therapeutics（AKRO）披露2笔公司内部人交易情况。高管Young Jonathan于2025年2月3日卖出5100股。 2025年2月5日 高管 Young Jonathan 2025年2月3日 卖出 4900 54.06 26.49万 2025年2月5日 高管 Young Jonathan 2025年2月3日 卖出 5100 53.57 27.32 ...